Stock Events

Stock Events

Acelrx Pharmaceuticals 

0
66
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 12Expected
Q1 2026
Q2 2026
Next
-0.06
-0.05
-0.04
-0.03
Expected EPS
-0.04487
Actual EPS
N/A

Financials

-47,856.1%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
25,808.32Revenue
-12.35MNet Income

Analyst Ratings

$2.28Average Price Target
The highest estimate is ⁦2.28⁩.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow R5X.STU. It's not an investment recommendation.
Rocket Lab
5
RKLB
Microsoft
4
MSFT
Amazon
4
AMZN
Tesla
4
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap368.89B
Merck & Co., Inc. is a leading global biopharmaceutical company that competes with Talphera in the development and marketing of prescription medicines, vaccines, biologic therapies, and animal health products.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc. is a global pharmaceutical corporation which competes directly with Talphera in various therapeutic areas, including oncology, rare diseases, and immunology.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol Myers Squibb is a global biopharmaceutical company that competes with Talphera in the discovery, development, and delivery of innovative medicines that help patients prevail over serious diseases.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need, competing with Talphera in the fields of antiviral drugs, cancer, and other diseases.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie Inc. is a research-based biopharmaceutical company that develops and markets advanced therapies, competing with Talphera in areas such as immunology and oncology.
AMGEN
AMGN
Mkt Cap251.94B
Amgen Inc. is one of the world's leading biotechnology companies, competing with Talphera in developing innovative human therapeutics, including treatments for serious illnesses.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson is a comprehensive healthcare company that competes with Talphera through its pharmaceutical segment, developing drugs for a wide range of medical conditions.
Novartis
NVS
Mkt Cap303.67B
Novartis AG is a global healthcare company based in Switzerland that competes with Talphera in researching, developing, manufacturing, and marketing a broad range of healthcare products.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Roche competes with Talphera in the pharmaceutical sector, particularly in oncology and virology.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biopharmaceutical company that competes with Talphera in developing and commercializing prescription medicines for several therapeutic areas, including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

About

Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
Show More
CEO
Vincent J. Angotti
Employees
12
Country
United States
ISIN
US00444T1007
WKN
000A3DWPN

Listings

MU
DE
R5X.MU
F
DE
R5XA.F
STU
DE
R5XA.STU
XNAS
US
TLPH

0 Comments

Share your thoughts

FAQs

What is Acelrx Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Acelrx Pharmaceuticals stocks are traded under the ticker R5X.STU.
When is the next Acelrx Pharmaceuticals earnings date?▼
Acelrx Pharmaceuticals is going to release the next earnings report on November 12, 2026.
What were Acelrx Pharmaceuticals earnings last quarter?▼
R5X.STU earnings for the last quarter are -0.05 EUR per share, whereas the estimation was -0.05 EUR resulting in a +4% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Acelrx Pharmaceuticals revenue for the last year?▼
Acelrx Pharmaceuticals revenue for the last year amounts to 25,808.32 EUR.
What is Acelrx Pharmaceuticals net income for the last year?▼
R5X.STU net income for the last year is -12.35M EUR.
How many employees does Acelrx Pharmaceuticals have?▼
As of November 7, 2026, the company has 12 employees.
In which sector is Acelrx Pharmaceuticals located?▼
Acelrx Pharmaceuticals operates in the Health & Wellness sector.
When did Acelrx Pharmaceuticals complete a stock split?▼
The last stock split for Acelrx Pharmaceuticals was on October 26, 2022 with a ratio of 1:20.
Where is Acelrx Pharmaceuticals headquartered?▼
Acelrx Pharmaceuticals is headquartered in SAN MATEO, United States.